Aging is the greatest risk factor for most diseases including cancer, cardiovascular disorders,
and neurodegenerative disease. There is emerging evidence that interventions that improve …

Introduction This meta-analysis aimed to characterize the nature and magnitude of amyloid
(Aβ)-related cognitive impairment and decline in cognitively normal (CN) older individuals …

Glial fibrillary acidic protein (GFAP), an astrocytic cytoskeletal protein, can be measured in
blood samples, and has been associated with Alzheimer's disease (AD). However, plasma …

Alzheimer's disease (AD) is the most common form of dementia. Currently, there is no
effective medication for the prevention or treatment of AD. This has led to the search for …

Worldwide there are over 46 million people living with dementia, and this number is
expected to double every 20 years reaching about 131 million by 2050. The cost to the …

Background Alzheimer's disease (AD) is a devastating neurodegenerative ailment having
pathological hallmarks of plaques due to amyloid β (Aβ) peptides and neurofibrillary tangles …

Objective To investigate the influence of microglial activation in the early stages of
Alzheimer's disease trajectory, we assessed the relationship between microglial activation …

Higher body mass index (BMI) in late-life has recently been considered as a possible
protective factor for Alzheimer's disease (AD), which yet remains conflicting. To test this …

Alzheimer's disease (AD) is a chronic, progressive neurodegenerative condition marked by
cognitive impairment. Although coconut oil has been shown to be potentially beneficial in …

Alzheimer's disease (AD) is progressive neurodegenerative disorder characterized by
accumulation of senile plaques, neurofibrillary tangles (NFT) and neurodegeneration. The …